Corin Group Launches FX Solutions Reverse Shoulder System In U.S.

TAMPA, Fla., Feb. 22, 2017 /PRNewswire/ — Corin Group announced today the launch of the Humelock Reversed Shoulder System, a device used to treat patients with both a massive rotator cuff tear and a severe form of shoulder arthritis. The condition, known as cuff tear arthropathy, causes pain and reduced mobility in the arm and shoulder.

The Humelock Reversed Shoulder System, which was developed by FX Solutions, a privately-held upper extremities technology company based near Lyon, France, received FDA clearance for the device in January 2017. The device is already available in Europe and other international markets.

Corin Group holds a distribution agreement for the device, as well as the Humelock II™ Cementless and Cemented Anatomical and Reversible Fracture Shoulder Systems. The agreement includes distribution rights in the United States, Germany and the United Kingdom.

“Our partnership with FX Solutions allows Corin to increase their offering in shoulder arthroplasty, whilst we continue to expand solutions in hip and knee. Our goal is to provide surgeons, hospitals, health systems, and patients with a new and comprehensive approach to orthopaedics and joint replacement,” said Paul Berman, President, Corin USA. “The launch of the Humelock Reversed Shoulder System means patients in the U.S. will have access to an important new option for reverse shoulder replacement.”

“Our continuing partnership with Corin provides U.S. clinicians access to our surgeon-designed shoulder systems, which have demonstrated clinical success in European markets,” said FX Solutions’ President and CEO Jean-Jacques Martin. “Corin is a valued partner committed to innovation that improves health outcomes and increases both patient and surgeon satisfaction. We look forward to continued success together.”

About Corin Group

Corin is a European orthopaedic manufacturer based in the UK that markets its products throughout the world.

Corin is committed to:

…improving patient satisfaction with personalized technologies that optimize our clinically proven joint replacements
…delivering a personal approach to our customers, combining the spirit of our local companies with the strength of our global, integrated organization
…empowering and rewarding our global talented teams to deliver excellence to our customers

For further information about Corin, please visit

This news release contains forward-looking statements. These statements appear in a number of places in this news release and include statements regarding our intentions, beliefs or current expectations, concerning, among other things, our results of operations, turnover, financial condition, liquidity, prospects, growth, strategies, new products, the level of new launches and the markets in which we operate. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ markedly from those in the forward-looking statements as a result of various factors. We undertake no obligation publicly to revise any forward-looking statements, except as may be required by law.



Related Links

Active Implants Appoints Ted Davis President and Chief Executive Officer

February 22, 2017

MEMPHIS, Tenn.–(BUSINESS WIRE)–Active Implants, a company that develops orthopedic implant solutions, today announced that Ted Davis has been appointed president and chief executive officer. Davis succeeds Henry Klyce, who will continue as chairman of the board.

A current member of the Active Implants board, Davis has 25 years of experience in the life sciences industry as an investor and senior executive, including chief executive officer of MicroPort Orthopedics and president of its predecessor Wright Medical Technology’s global OrthoRecon division from 2012 through 2015. Prior to leading the carve out and integration of the OrthoRecon platform, Davis led Wright’s business development, corporate development and research & development functions from 2006 to 2012, with increasing responsibility for the business development, government affairs, national accounts, reimbursement, medical education and global research & development teams. Davis oversaw the acquisition and integration of a series of extremities and biologics platforms during Wright’s transformation into the market leader in the extremities market segment. Prior to joining Wright in 2006, Davis spent 10 years in the life sciences venture capital field, serving on the boards of multiple biotechnology and medical device companies while at MB Venture Partners and Vector Fund Management. He holds an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree in engineering from Vanderbilt University.

“Ted’s expert business vision, along with his extensive experience providing strategy and leadership at orthopedic companies, makes him an extraordinary fit for Active Implants,” Klyce said. “A proven leader with a track record of delivering results, Ted brings the experience necessary to guide us through our next stage of growth.”

“I am honored and excited to lead Active Implants as we prepare for the next phase of development for the NUsurface Meniscus Implant around the world,” Davis said. “We have an opportunity to fulfill a significant unmet need in the orthopedic market here in the U.S. and worldwide, helping the millions of patients with persistent knee pain following meniscectomy. I look forward to continuing to work with Henry, given his successful track record in the orthopedics and spine medical technology industry and the outstanding progress he has led in the clinical development programs for the NUsurface Meniscus Implant here at Active Implants.”

The NUsurface® Meniscus Implant is an investigational treatment for patients with persistent knee pain following medial meniscus surgery. It is made from medical grade plastic and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissues. The NUsurface Meniscus Implant mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint. The NUsurface Meniscus Implant has been used in Europe under CE Mark since 2008 and in Israel since 2011. Clinical trials are underway in the U.S., Europe and Israel to verify the safety and effectiveness of the NUsurface Meniscus Implant.

About Active Implants LLC

Active Implants LLC develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle. Active Implants is privately held with headquarters in Memphis, Tennessee. European offices are in Driebergen, The Netherlands, with R&D facilities in Netanya, Israel. For more information, visit

CAUTION Investigational device. Limited by United States law to investigational use.


Merryman Communications
Joni Ramirez, 323-532-0746

American Academy of Orthopaedic Surgeons names Thomas E. Arend, Jr. as new CEO

ROSEMONT, Ill., Feb. 21, 2017 /PRNewswire-USNewswire/ — The American Academy of Orthopaedic Surgeons (AAOS) announced the selection of Thomas E. Arend, Jr., CAE, to the position of Chief Executive Officer, effective April 1, 2017. As CEO, Arend will work directly with the AAOS Board of Directors and executive management team to oversee a staff of 250 and manage an annual budget of $60 million.

“The Academy is very pleased that Tom Arend, an experienced and proven health care leader, will serve as our next CEO,” said AAOS President Gerald R. Williams Jr., MD. “Tom is a strong strategic thinker and visionary leader who understands the complexities of the changing health care arena. He will serve our members and staff well.”

Arend currently serves as Executive Vice President, Chief Operating Officer and General Counsel at the American College of Cardiology (ACC), a 52,000-member organization in Washington, DC. In this role, he is responsible for ensuring the ACC’s overall financial health, operational effectiveness and strategic direction. In addition, he is responsible for all aspects of the College’s legal, risk management and compliance activities.

Since joining the ACC in 2004, Arend has led the College through two CEO transitions and played critical roles in the development of comprehensive relationship with industry standards and code of ethics, as well as the College’s  five-year strategic plan and more recent governance restructuring.  Arend has also spearheaded several successful collaborations with other medical societies and stakeholders that directly benefit the ACC’s mission to transform cardiovascular care and improve heart health. Most recently, he was responsible for the addition of hospital accreditation services to the ACC’s suite of hospital quality improvement offerings.

“I am excited to join the AAOS, and I am honored and humbled to be leading this strong and vibrant organization,” said Arend. “I look forward to advancing the mission of the Academy and working closely with the volunteer leaders, members and staff.”

Prior to joining ACC, Arend served as an attorney at Shaw Pittman, LLP and Jenner & Block. He received a Juris Doctor degree from the Washington College of Law at The American University, a Master of Arts in International Law and Diplomacy from The Fletcher School of Law and Diplomacy at Tufts University, and a Bachelor of Arts from Kenyon College. He is a member of the Maryland and District of Columbia Bar associations, the American Society of Association Executives and the American College of Healthcare Executives.

Arend is replacing AAOS CEO Karen L. Hackett, FACHE, CAE, who is retiring after 14 years at the organization’s helm. The AAOS Board of Directors retained executive search firm Korn Ferry to lead the search for a new CEO.

About the AAOS
With more than 39,000 members, the American Academy of Orthopaedic Surgeons is the world’s largest medical association of musculoskeletal specialists. The AAOS provides educational programs for orthopaedic surgeons and allied health professionals, champions and advances the highest quality musculoskeletal care for patients, and is the authoritative source of information on bone and joint conditions, treatments and related issues.

Visit AAOS at: for bone and joint health news, stats, facts, images and interview requests. for inspirational patient stories, and orthopaedic surgeon tips on maintaining bone and joint health, avoiding injuries, treating musculoskeletal conditions and navigating recovery. for patient information on hundreds of orthopaedic diseases and conditions.

SOURCE American Academy of Orthopaedic Surgeons

Medacta Enters Shoulder Surgery Market with Successful First Surgery Using its Medacta Shoulder System

February 16, 2017

CASTEL SAN PIETRO, Switzerland–(BUSINESS WIRE)–Building on its success in the hip, knee and spine product areas, family-owned orthopedics leader Medacta International is expanding into the shoulder arthroplasty market. The company today announced the completion of the first surgery utilizing its Medacta Shoulder System, performed by Professor Ralph Hertel in Bern, Switzerland.

“The procedure was a success,” said Professor Hertel, who has specialized in shoulder and elbow surgery for more than two decades. “As expected, the early postoperative phase and hospital stay were uneventful, and the patient is on a smooth path to recovery. We’re very pleased.”

The Medacta Shoulder System is a modular solution that features a broad range of options, including wide-ranging sizes, adjustable offset, innovative configurations and the CT-based MyShoulder 3D preoperative planning solution for patient-specific humeral and glenoid guides.

“With the Medacta Shoulder System, we are entering the fast growing upper extremity market with the same patient-centric vision and ambition that characterized our growth and success in knee, hip and spine technology: delivering innovation through high-level surgical education and providing real benefits to patients and healthcare system sustainability,” said Alberto Siccardi, President and Founder of Medacta International.

Designed by a group of expert surgeons from Europe, Australia and the United States, the Medacta Shoulder System also offers the flexibility to move from a total to reverse arthroplasty without the need to revise all components.

“The most important consideration in orthopedics and joint replacement is not only to improve implant design, but also to elevate design standards. With the Medacta Shoulder System, we aim to solve the issues related to implant design, polyethylene wear and the reproducibility of results,” said Francesco Siccardi, Executive Vice President of Medacta International.

The Medacta Shoulder System is currently under clinical evaluation by the surgeon design team and will be available in 2018.

For more information about Medacta, please visit or follow @Medacta on Twitter.

About Medacta

Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS®system and total knee replacement with MyKnee® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries. To learn more about Medacta International, please visit or follow @Medacta on Twitter.


For Medacta International, Inc.
Jill Bongiorni, 516-729-2250

Osteosynthesis Devices Market is Expected to Reach a Value of USD 9.9 Billion by 2024

The osteosynthesis devices market size is expected to reach a value of USD 9.9 billion by 2024, according to a new report by Grand View Research, Inc. The worldwide prevalence of conditions like osteoporosis and osteomalacia, coupled with heavily occurring road traffic injuries/accidents and sporting injuries support the demand for osteosynthesis devices worldwide.

Osteoporosis, a disease resulting in weakening of bones is responsible for causing more than 8.9 million fractures annually. Forearm, humerus, hip and spine are the most commonly affected areas in patients suffering from the disease. The incidence and economic burden of osteoporosis is increasing worldwide, and patients 65 years old or over are at maximum risk of getting affected.

The geriatric population accounted for 46.2 million in 2014, and is increasingly rising. It is projected that by the year 2060, the number of older population will be twice than that of 2014. The rising incidence of osteoporosis and increasing count of the geriatric population is expected to drive demand for osteosynthesis devices in the coming years.

On the other hand, road traffic deaths are at the focal point of a crisis facing public health and development. The WHO reported that accidents/injuries majorly affect the low- and middle-income countries. Road accidents can cause severe injuries such as broken bones and fractures and requires immediate orthopediccare and attention.



Orthopedic Devices Market Global Briefing 2017

LONDON, Feb. 14, 2017 /PRNewswire/ — Orthopedic devices are used for restoring skeletal structure and joint movements in various fractures, abnormal growth of bones, soft tissue damage, trauma or other deformities. These devices are implanted by surgical procedures or can be externally attached through minimally invasive procedures. Orthopedic devices can be classified as joint implants, internal and external fixation devices.

Americas was the largest region in the orthopedic devices market in 2016, accounting for around 40% of the market share. Europe was the second largest region accounting for over 30% of the market share. Asia was the third largest region accounting for around 16% of the market share.

Biodegradable implants are increasingly being used in trauma orthopedic surgeries. Biodegradable implants are used to replace a missing biological structure, support a damaged biological structure, and enhance the existing bone structure. Biodegradable products such as reabosorbable polymers composed of polyglycolic acid and poly lactic acid manufactured in the form of plates, screws, and pins are replacing traditional devices like plates and screws which are more expensive. Surgeons are preferring biodegradable implants to replace conventional implants, as biodegradable implants can be engineered to provide temporary support for bone fractures; can degrade at a rate matching new tissue formation; can eliminate the need for second surgery, are highly useful in fracture fixation in children; and result in less implant related infections. For instance, Stryker Corp. offers orthrobiologics such as bone repair biodegradable products that are used in bone regeneration and bone healing, soft tissue regeneration and muscle connection to bone.

Download the full report:

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at
Tel: +44 208 816 85 48

SOURCE ReportBuyer

Hospital For Special Surgery Collaborates With Stamford Health

STAMFORD, Conn. — Stamford Health and Hospital for Special Surgery (HSS) formally announced a collaboration to create the premier center for advanced orthopedic care serving Connecticut and New England.

HSS Orthopedics at Stamford Health will provide a level of inpatient and ambulatory care unrivaled in the region. Under the collaboration, Stamford Health will adopt HSS best practices across the entire orthopedic service line, and surgeons from HSS in New York City will be providing care through HSS Orthopedics at Stamford Hospital.

HSS is the world’s leading academic medical center focused on musculoskeletal health and has been ranked the No. 1 hospital for orthopedics in the U.S. for the past seven consecutive years by U.S News & World Report. HSS leads the field of orthopedics nationwide for successful outcomes, and lowest infection, complication and revision rates.

“We believe this strategic and innovative relationship with HSS will elevate our institution to the forefront of musculoskeletal services and further differentiate us from others in the region,” said Brian G. Grissler, President and CEO, Stamford Health. “Through this collaboration, we will create a new Department of Orthopedic Surgery that integrates best practices and expands our capabilities.”

“We are drawing upon the very best skills, talent and resources of HSS and Stamford Health in what is truly a transformational collaboration between our two organizations,” said Louis A. Shapiro, President and CEO, Hospital for Special Surgery. “This revolutionary alliance will bring world-class orthopedic care closer to home for thousands of Connecticut residents, so fewer will need to leave the state for such care.”

HSS Orthopedics at Stamford Health will be available on a dedicated fifth floor of the acclaimed new Stamford Hospital building late this year, and later this month at Tully Health Center.

“Stamford Health has been providing tertiary care to the residents of Fairfield County for more than 120 years,” Grissler said. “Building upon our existing foundation of service, Magnet status nursing and a brand new hospital, this collaboration will take their orthopedic services to the next level.”

HSS has provided pre-, post- and non-surgical care in Connecticut since 2001. The 20,000 square foot HSS Outpatient Center at Chelsea Piers Connecticut in Stamford will continue to provide those services, as will the neighboring HSS-Stamford Health Sports Rehab facility.

Zimmer Biomet Announces the International Release of the Innovative Subchondroplasty® Procedure

WARSAW, Ind., Feb. 7, 2017 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, announced today the international release of the Subchondroplasty® (SCP®) Procedure.  The Company received CE Mark approval for the commercialization of its SCP Procedure to facilitate distribution in the European Union (EU) and other countries that recognize the CE Mark.  Zimmer Biomet also received approval for distribution in Canada, Singapore, Malaysia and Hong Kong.

The SCP Procedure is a minimally invasive outpatient intervention that addresses the defects associated with subchondral bone marrow lesions (BMLs). Diagnosed using an MRI and physical exam, BMLs are associated with stress fractures or micro-fractures of the bone adjacent to the joint. Left untreated, these defects may lead to cartilage degeneration, limited function, pain and a greater risk for joint deterioration.

SCP is performed to repair chronic BMLs by filling them with AccuFill® Bone Substitute Material, a porous injectable calcium phosphate (CaP). The bone substitute is then slowly resorbed and replaced with healthy bone, repairing the bone defect.

The procedure is usually performed along with arthroscopy for visualization and treatment of findings inside the joint. In some cases, an open or mini-open procedure is necessary for access to the defect.

“The Subchondroplasty procedure addresses a previously unmet need in my practice for patients with chronic and painful bone marrow lesions,” said Dr. Christopher Baker, orthopaedic surgeon at Florida Orthopedic Institute in Tampa, Fla. “These patients no longer benefit from conservative treatment, yet are not ready for total joint replacement surgery.”

Initially used only in bone defects of the knee, the SCP Procedure has been successfully performed in other areas including bones of the foot, ankle and hip. Zimmer Biomet now owns 36 patents and eight trademarks in this area, with numerous others still pending.

“The international release of the Subchondroplasty Procedure is a major milestone for our company and for patients with chronic bone marrow lesions,” said David Nolan, Zimmer Biomet Group President, Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle, Office Based Technologies and Zimmer Biomet Signature Solutions. “The procedure offers a tool that fills a gap in the patient treatment algorithm for the surgeon. We are eager to begin our international commercial launch.”

For more information on the SCP Procedure, please visit

About Zimmer Biomet

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit or follow Zimmer Biomet on Twitter at

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes.  Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially.  For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC.  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC.  We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports.  Accordingly, such forward-looking statements speak only as of the date made.  Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this news release.

To view the original version on PR Newswire, visit:

SOURCE Zimmer Biomet Holdings, Inc.

News Provided by Acquire Media

Breakthrough Medical Imaging Solution Micro C™ Banks Additional $700k Seed Funding

SAVANNAH, GEORGIA, UNITED STATES, February 3, 2017 / — As Micro C™ targets the high growth market of surgeries of the extremities, Greg Kolovich MD/MPH and Chief Medical Officer, Evan Ruff, CEO, and Kirby Sisk, COO are leveraging the additional funding to complete Q2 2017 Micro C™ milestones: prototype build, beta testing, FDA submission, and go-to-market launch activities including demonstrations at leading professional academies for orthopedic surgeons.

“At our sessions with orthopedic surgeons and ambulatory surgery center management, the feedback is consistent: They want to use the Micro C as soon as commercially available,” remarks Dr. Kolovich. “They are impressed with how we have incorporated multiple innovations into a compact digital X-ray and multi-modal camera that also integrates real-time, HIPPA compliant data and image transmission together with accurate billing and much greater accuracy, clarity, safety, and speed.”

Georgia-based technology boosters, including the Technology Association of Georgia and Georgia Tech’s Advanced Technology Development Center (ATDC) have recognized Micro C’s prowess with TAG’s Most Innovative Company award and ATDC’s Geekend Pitch Contest first place award.

“With seven patents filed, we believe that the intellectual property we created is not only winning us recognition, but will also contribute to building the value of our product and our company significantly,” explained CEO Evan Ruff. With responsibility for the production of the Micro C emitter, table and accessories, COO Kirby Sisk added, “Combining a compact and complex device with software, consumables, and service support will demand skills and resources that we are rapidly bringing on board with our investors’ confidence and backing.”

About Micro C™

Micro C™ is a groundbreaking medical imaging solution designed for surgeons and physicians treating disorders of the extremities that combines a compact, hand-held X-ray and digital still, video and infrared cameras, software, service and consumables. It is designed to deliver greater accuracy, clarity, safety, and speed, replacing 60-year-old x-ray and fluoroscopy equipment that is bulky, expensive and less safe. Invented by Greg Kolovich MD/MPH, experienced orthopedic surgeon and Chief Medical Officer and Founder, he leads the founding team of fellow Georgia Institute of Technology graduates with Evan Ruff as CEO and Kirby Sisk as COO.

Learn more about Micro C Imaging online including Facebook and Twitter.

Media Contact
Murem Sharpe

Murem Sharpe
Micro C Imaging
email us here

Powered by EIN Presswire

Flower Orthopedics Launches FlowerAdvantage, an Ambulatory Surgery Center Efficiency and Savings Partnership

HORSHAM, Pa., Feb. 3, 2017 /PRNewswire/ — Flower Orthopedics, the leader in Ready-For-Surgery™ extremity implant systems, announces the release of its FlowerAdvantage™ Program, a multi-level initiative designed to reduce the costs of providing care in the ambulatory surgery center setting.  “The FlowerAdvantage™ Program has four pillars that generate costs savings and positively impact the operations of surgery centers, while providing patients with the highest standard of care,” said Oliver Burckhardt, President and CEO of Flower Orthopedics.

The four pillars of costs savings in the FlowerAdvantage™ Program are FlowerBucketPrice™ where all components needed for the case are identified, bundled and sold without any hidden or extra costs; Flower ECO Implant™ Line is a value based implant portfolio capable of accommodating challenging reimbursement scenarios; FlowerBuyBack™ Program allows the surgery center to sell back to Flower used single-use instruments from the case; and Flower Ready-For-Surgery™ eliminates operational costs associated with processing trays, inherent case delays & cancellations, and infection risks.

“The FlowerAdvantage™ Program meets a significant unmet need in the outpatient surgery market. With bundled payments and other initiatives driving down reimbursements, surgery centers must find other means to cut costs without diminishing patient care,” said Mr. Burckhardt.  The FlowerAdvantage™ Program provides costs savings through the efficiency-based value proposition that other companies cannot provide. The Ready-For-Surgery FlowerCube™ relieves the burden of the surgery center to clean, sterilize, track and manage implant trays, saving considerable time and cost. Flower is focused on providing its customers with many options that improve the level of patient care, while reducing the costs incurred by the healthcare system as a whole.

About Flower: Flower Orthopedics was founded in 2012 to develop technologies that drive efficiencies translating into cost savings for all stakeholders in healthcare. Flower’s development team works tirelessly with leading surgeons to create advanced implant and instrument systems, that are always Ready-For-Surgery.

To view the original version on PR Newswire, visit:

SOURCE Flower Orthopedics